Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 26;15(4):405.
doi: 10.3390/ph15040405.

In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls

Affiliations

In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls

Muanpetch Rachayon et al. Pharmaceuticals (Basel). .

Abstract

Major depressive disorder and major depressive episodes (MDD/MDE) are characterized by the activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS). Cannabidiol (CBD) is a phytocannabinoid isolated from the cannabis plant, which is reported to have antidepressant-like and anti-inflammatory effects. The aim of the present study is to examine the effects of CBD on IRS, CIRS, M1, T helper (Th)-1, Th-2, Th-17, T regulatory (Treg) profiles, and growth factors in depression and healthy controls. Culture supernatant of stimulated (5 μg/mL of PHA and 25 μg/mL of LPS) whole blood of 30 depressed patients and 20 controls was assayed for cytokines using the LUMINEX assay. The effects of three CBD concentrations (0.1 µg/mL, 1 µg/mL, and 10 µg/mL) were examined. Depression was characterized by significantly increased PHA + LPS-stimulated Th-1, Th-2, Th-17, Treg, IRS, CIRS, and neurotoxicity profiles. CBD 0.1 µg/mL did not have any immune effects. CBD 1.0 µg/mL decreased CIRS activities but increased growth factor production, while CBD 10.0 µg/mL suppressed Th-1, Th-17, IRS, CIRS, and a neurotoxicity profile and enhanced T cell growth and growth factor production. CBD 1.0 to 10.0 µg/mL dose-dependently decreased sIL-1RA, IL-8, IL-9, IL-10, IL-13, CCL11, G-CSF, IFN-γ, CCL2, CCL4, and CCL5, and increased IL-1β, IL-4, IL-15, IL-17, GM-CSF, TNF-α, FGF, and VEGF. In summary, in this experiment, there was no beneficial effect of CBD on the activated immune profile of depression and higher CBD concentrations can worsen inflammatory processes.

Keywords: biomarkers; cytokines; depression; inflammation; mood disorders; neuroimmunomodulation; psychiatry.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Dot plots of enriched GO functions representing upregulated genes by cannabidiol (1.0 µg/mL).
Figure 2
Figure 2
Dot plots of enriched GO functions representing downregulated genes by cannabidiol (1.0 µg/mL). p adjust: color intensity indicates variable values of p values.
Figure 3
Figure 3
Protein–protein interaction network of high-confidence interactions of the upregulated and downregulated genes as well as gene members of GO:0042531 (positive regulation of phosphorylation of STAT protein) and GO:0048245 (eosinophil chemotaxis).

Similar articles

Cited by

References

    1. Maes M., Carvalho A.F. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Mol. Neurobiol. 2018;55:8885–8903. doi: 10.1007/s12035-018-1016-x. - DOI - PubMed
    1. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012;36:764–785. doi: 10.1016/j.neubiorev.2011.12.005. - DOI - PubMed
    1. Ogłodek E.A., Szota A., Just M.J., Moś D., Araszkiewicz A.S. Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. Pharmacol. Rep. 2014;66:920–926. doi: 10.1016/j.pharep.2014.06.001. - DOI - PubMed
    1. Eyre H.A., Air T., Pradhan A., Johnston J., Lavretsky H., Stuart M.J., Baune B.T. A meta-analysis of chemokines in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2016;68:1–8. doi: 10.1016/j.pnpbp.2016.02.006. - DOI - PMC - PubMed
    1. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20:127–150. doi: 10.1007/s10787-011-0111-7. - DOI - PubMed

Grants and funding

LinkOut - more resources